- Home
- STR vs BEAM Comparison
STR vs BEAM Comparison
Compare STR & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STR
- BEAM
- Stock Information
- Founded
- STR 2016
- BEAM 2017
- Country
- STR United States
- BEAM United States
- Employees
- STR N/A
- BEAM N/A
- Industry
- STR Oil & Gas Production
- BEAM Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- STR Energy
- BEAM Health Care
- Exchange
- STR Nasdaq
- BEAM Nasdaq
- Market Cap
- STR 1.7B
- BEAM 1.9B
- IPO Year
- STR N/A
- BEAM 2020
- Fundamental
- Price
- STR $24.65
- BEAM $23.58
- Analyst Decision
- STR Buy
- BEAM Buy
- Analyst Count
- STR 6
- BEAM 11
- Target Price
- STR $29.40
- BEAM $45.90
- AVG Volume (30 Days)
- STR 842.3K
- BEAM 1.3M
- Earning Date
- STR 11-06-2024
- BEAM 11-05-2024
- Dividend Yield
- STR 6.03%
- BEAM N/A
- EPS Growth
- STR N/A
- BEAM N/A
- EPS
- STR N/A
- BEAM N/A
- Revenue
- STR $618,668,000.00
- BEAM $349,643,000.00
- Revenue This Year
- STR $6.85
- BEAM N/A
- Revenue Next Year
- STR N/A
- BEAM $6.04
- P/E Ratio
- STR N/A
- BEAM N/A
- Revenue Growth
- STR 13.74
- BEAM 328.73
- 52 Week Low
- STR $19.88
- BEAM $20.84
- 52 Week High
- STR $25.95
- BEAM $49.50
- Technical
- Relative Strength Index (RSI)
- STR 63.40
- BEAM 45.28
- Support Level
- STR $23.31
- BEAM $23.67
- Resistance Level
- STR $25.52
- BEAM $25.87
- Average True Range (ATR)
- STR 0.73
- BEAM 2.23
- MACD
- STR 0.06
- BEAM -0.24
- Stochastic Oscillator
- STR 74.93
- BEAM 19.58
About STR Sitio Royalties Corp.
Sitio Royalties Corp is a pure-play mineral and royalty company. The group focuses on investing in mineral and royalty interests in the Permian and other productive U.S. oil basins.
About BEAM Beam Therapeutics Inc.
Beam Therapeutics Inc is a biotechnology company engaged in creating genetic medicines based on its base editing technology. This technology enables a new class of genetic medicines that targets a single base in the genome without making a double-stranded break in the DNA. The company's portfolio comprises Gene Correction, Gene Modification, Gene Activation, Gene Silencing, and Multiplex Editing. The company's pipeline programs consist of BEAM-101, ESCAPE, BEAM-302, BEAM-301, and BEAM-201.